Why the study?
Non-ischaemic heart failure with reduced ejection fraction requires novel biomarkers for early identification, clinical management, and risk assessment.
Do whole peripheral blood miRNA signatures discriminate non-ischaemic HF-REF patients from controls and correlate with disease severity?
Do whole peripheral blood miRNA signatures discriminate non-ischaemic HF-REF patients from controls and correlate with disease severity?
Peripheral blood miRNA signatures can identify non-ischaemic HF-REF and correlate with LVEF, highlighting their potential as novel biomarkers for assessing heart failure severity.
No takes yet. Share an insight, caveat, or question.
miRNA signatures merit prospective validation as biomarkers in non-ischaemic HF-REF; leaves open clinical adoption without further trials.
Vogel et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: